Biomea Fusion, Inc..
BMEA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Biomea Fusion, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing irreversible small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, is designed to address the root cause of diab...Show More
Better Health for All
0
Biomea Fusion's core business is entirely devoted to developing treatments for serious diseases like type 1 and type 2 diabetes and genetically defined cancers.
1
Its lead product candidate, icovamenib (BMF-219), has shown significant positive health benefits in clinical trials, including a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide in severe insulin-deficient patients.
2
As the company is in the clinical trial phase and has no commercialized products, it currently generates no revenue from products, thus no harmful revenue. However, the company's safety record has faced scrutiny, with the FDA placing a clinical hold on BMF-219 trials in June 2024 due to observed liver enzyme elevations at higher doses.
3
While these elevations were dose-related, transient, returned to baseline, and no serious liver injury or impairment occurred, this constitutes a notable safety incident.
4
The FDA lifted the hold in September 2024 after Biomea revised its protocol, including recommendations for a 100mg starting dose, single-step dose escalation, and increased monitoring of liver enzymes.
5
The company's clinical trials are multi-site, randomized, double-blind, and placebo-controlled, with approximately 200 patients in the Phase 2b COVALENT-111 study and 150 patients in the Phase 2 COVALENT-112 study, demonstrating adherence to standard ethical practices for clinical research.
6
There is no information available regarding the company's approach to patent flexibility.
Fair Money & Economic Opportunity
0
No evidence available to assess Biomea Fusion, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data is available across the provided articles to assess Biomea Fusion, Inc. against the Fair Pay & Worker Respect KPIs. While provides a CEO salary of $389,151 and a lowest paid salary of $70,424, it does not provide median employee compensation, which is required to calculate the CEO to median pay ratio.
1
Similarly, there is no data on the share of the workforce earning a living wage, collective bargaining coverage, safety incident rates, pay equity ratios, worker engagement scores, or the percentage of employees on insecure contracts or with health insurance coverage. mentions a 35% staff layoff, but this is not voluntary turnover.
2
An FDA clinical hold due to liver toxicity concerns was noted, but this is a product-related regulatory action, not a labor-law or human-rights violation.
3
Fair Trade & Ethical Sourcing
0
The provided article from Sustainalytics focuses on the company's ESG risk rating and industry ranking, but does not contain any specific data or information related to fair trade practices, ethical sourcing, or supply chain management for any of the defined KPIs.
1
Honest & Fair Business
0
Levi & Korsinsky commenced an investigation of Biomea Fusion, Inc. concerning possible violations of federal securities laws, triggered by the FDA placing a clinical hold on the company's Phase I/II clinical trials.
1
The company's corporate governance overview mentions a Code of Business Conduct and provides a contact email for compliance inquiries.
2
Kind to Animals
0
Biomea Fusion Inc. uses animals for preclinical validation of its lead product candidate, BMF-219, for diabetes treatment.
1
No information is available regarding the company's animal testing policy, alternative testing methods, cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
2
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles for any of the KPIs related to BMEA.US's association with arms manufacturing, military contracts, or conflict facilitation. All articles explicitly state a lack of data for BMEA.US regarding these metrics, focusing instead on broader industry trends or general defense spending.
1
Planet-Friendly Business
0
The provided articles, including investor reports and ESG summaries, explicitly state a lack of specific quantitative or qualitative data related to Biomea Fusion's planet-friendly business practices. No information is available on environmental impact, emissions, renewable energy use, water usage, waste diversion, or any other relevant sustainability metrics for scoring against the rubric.
1
Respect for Cultures & Communities
0
No specific, concrete data points or facts relevant to the 'Respect for Cultures & Communities' value were found in the provided articles for Biomea Fusion, Inc. The articles either focused on general career information, ESG risk ratings without specific community details, or explicitly stated that no relevant data was available or accessible.
1
Safe & Smart Tech
0
No evidence available to assess Biomea Fusion, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found across the provided articles for any of the KPIs related to Zero Waste & Sustainable Products. The articles primarily focus on financial results, strategic realignment, workforce reduction, and clinical development. Several articles explicitly state that no data relevant to waste management, sustainable products, or circular economy principles was found.
1